Think the Fed will likely postpone any rate cuts to next year. Loosening any earlier risks negating all their effort over the past 2 years to contain inflation. Economy seems to be in decent condition and unemployment rate remains low. Little reason to cut early.
$Trillium Therapeutics(TRIL)$operating planis on track. Focus is on strong executionto ensure a robust flow of new data starting in 4Q 2021 and 2022. Holding $265m cash position. Trillium’s position as a leading CD47 company makes it a buy at $6.10
$Myovant Sciences Ltd.(MYOV)$ Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc) https://s.flashalert.me/IPr3X
$Jumia Technologies AG(JMIA)$Huawei has announced a partnership with Africa’s e-commerce leader Jumia. The partnership will enable customers searching for products on the Petal Search shopping channel to conveniently click through to the Jumia product page and buy instantly